HPV Country Profile

Statistics and Data Analytics


cases in 2018



deaths in 2018

Status of National HPV Vaccination Programme

The HPV vaccine is currently included in Libya’s national immunization program.


General Information

Human Papillomavirus

Burden of HPV infection

In Libya, about 2.7% of women in the general population are estimated to have HPV type 16 or 18 at a given time, which causes approximately 78.9% of invasive cervical cancers in the country.1

Burden of cervical cancer

Cervical cancer, caused by HPV, is the fourth leading cause of cancer deaths in women in Libya, causing at least 127 deaths annually among the population of 2.3 million women aged 15 years and older who are at risk for the disease.1,2 Between 2012 and 2018, the number of deaths every year due to cervical cancer increased by 33% (95 in 2012 to 127 in 2018), and if decisive action is not taken at the national level, annual deaths due to the disease will increase again by 144% by 2040, reaching 311 deaths per year.3 In Libya, at least 319 women are newly diagnosed with cervical cancer each year.

11.5 per 100,000 women in Libya contract cervical cancer annually and 4.9 per 100,000 Libyan women die due to the disease each year. Among countries in the MENA region (as defined by UNAIDS), Libya’s death and incidence rates due to cervical cancer are relatively high. For example, Somalia and Morocco have the highest incidence and mortality rates, with 24.0 and 17.2 women per 100,000 being newly diagnosed with cervical cancer annually and at least 21.9 and 12.6 women per 100,000 dying due to cervical cancer per year, respectively. Whereas Iran, Iraq and Yemen have the lowest (around 2 per 100,000 women are diagnosed per year and about 1 per 100,000 die because of cervical cancer annually).2

Cervical cancer incidence and mortality rate projections
Research and Publications
  1. Hweissa, Nada Ab, and Tin Tin Su. “Awareness of Cervical Cancer and Socio-Demographic Variations among Women in Libya: An Exploratory Study in Az-Zawiya City.” European Journal of Cancer Care, vol. 27, no. 1, 2018, p. e12750, doi:10.1111/ecc.12750.
  2. Elghblawi, Ebtisam. “75: Hpv Infection in Women: Knowledge, Attitudes and Behaviors and the Implications for Libyan Healthcare.” BMJ Open, vol. 7, no. Suppl 1, Feb. 2017, p. bmjopen-2016-015415.75, doi:10.1136/bmjopen-2016-015415.75.
  3. Khaial, F. Ben, et al. “Cervical Cancer in North-Eastern Libya: 2000–2008.” Journal of Obstetrics and Gynaecology, vol. 34, no. 6, Aug. 2014, pp. 523–26, doi:10.3109/01443615.2014.914478.
  4. Mistiri, Mufid El, et al. “Cancer Incidence in Eastern Libya: The First Report from the Benghazi Cancer Registry, 2003.” International Journal of Cancer, vol. 120, no. 2, 2007, pp. 392–97, doi:10.1002/ijc.22273.
  5. Akhtar, S. S., et al. “Cancer in Libya--a Retrospective Study (1981-1985).” African Journal of Medicine and Medical Sciences, vol. 22, no. 1, Mar. 1993, pp. 17–24, http://europepmc.org/abstract/med/7839877.
View all publications
No publication is available.
  1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Libya. Summary Report 27 July 2017. [19 October, 2018]

  2. Cancer Today. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  3. Cancer Tomorrow. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

Please notify us if you know of other resources, including academic publications, news articles and information that should be added to this page by emailing: hpvmena@gmail.com.